健脑益智方结合以tDCS为中心的认知康复防治认知障碍的疗效研究

注册号:

Registration number:

ChiCTR2200063826 

最近更新日期:

Date of Last Refreshed on:

2023-04-15 21:44:53 

注册时间:

Date of Registration:

2022-09-18 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

健脑益智方结合以tDCS为中心的认知康复防治认知障碍的疗效研究

Public title:

Jiannao Yizhi Formula combine transcranial direct current stimulation centered on prevention of the curative effect of cognitive impairment in cognitive rehabilitation

注册题目简写:

English Acronym:

研究课题的正式科学名称:

老年认知功能障碍的中医康复体系构建与评价研究

Scientific title:

Traditional Chinese Medicine (TCM) rehabilitation framework construction and assessment research for cognitive impairment in the elderly

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiMCTR2200006613

申请注册联系人:

刘宝虎 

研究负责人:

吴东宇 

Applicant:

Baohu Liu 

Study leader:

Dongyu Wu 

申请注册联系人电话:

Applicant telephone:

+86 18210826290

研究负责人电话:

Study leader's
telephone:

+86 13911202927

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

liubaohu2006@163.com

研究负责人电子邮件:

Study leader's E-mail:

wudongyu73@hotmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市朝阳区中环南路6号

研究负责人通讯地址:

北京市朝阳区中环南路6号

Applicant address:

6 Zhonghuan South Road, Chaoyang District, Beijing

Study leader's address:

6 Zhonghuan South Road, Chaoyang District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国中医科学院望京医院

Applicant's institution:

Wangjing Hospital, China Academy of Chinese Medical Sciences

研究负责人所在单位:

中国中医科学院望京医院

Affiliation of the Leader:

Wangjing Hospital, China Academy of Chinese Medical Sciences

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

CI2021A01410

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国中医科学院望京医院伦理委员会

Name of the ethic committee:

Wangjing Hospital, China Academy of Chinese Medical Sciences ethics committee

伦理委员会批准日期:

Date of approved by ethic committee:

2022-07-19 00:00:00

伦理委员会联系人:

王浩

Contact Name of the ethic committee:

Hao Wang

伦理委员会联系地址:

北京市朝阳区中环南路6号

Contact Address of the ethic committee:

6 Zhonghuan South Road, Chaoyang District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国中医科学院望京医院

Primary sponsor:

Wangjing Hospital, China Academy of Chinese Medical Sciences

研究实施负责(组长)单位地址:

北京市朝阳区中环南路6号

Primary sponsor's address:

6 Zhonghuan South Road, Chaoyang District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院望京医院

具体地址:

北京市朝阳区中环南路6号

Institution
hospital:

Wangjing Hospital, China Academy of Chinese Medical Sciences

Address:

6 Zhonghuan South Road, Chaoyang District, Beijing

经费或物资来源:

中国中医科学院科技创新工程项目

Source(s) of funding:

Scientific and technological innovation project of China Academy of Chinese Medical Sciences

研究疾病:

老年性痴呆、血管性痴呆  

Target disease:

Alzheimer disease,Vascular dementia

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

观察健脑益智方结合以tDCS为中心的认知康复防治认知障碍的疗效,探讨中西医结合防治认知障碍的优化方案  

Objectives of Study:

To observe Jiannao Yizhi Formula combine transcranial direct current stimulation centered the curative effect of cognitive rehabilitation prevention and treatment of cognitive impairment, the optimized plan for the prevention and control of traditional Chinese and western medicine combined with cognitive impairment

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.有其他脑部器质性疾病、抑郁症及精神病;
2.恶性肿瘤、药物过敏史、造血凝血功能障碍或合并严重的心肺功能障碍患者;
3.有其他因素引起的认知障碍或痴呆,如脑外伤、帕金森病等;
4.不能配合检查的患者(如中医四诊仪、经络检测仪及神经电生理评估等)。

Exclusion criteria:

1. Other organic brain diseases, depression, and mental illness;
2. Patients with malignant tumors, a history of drug allergy, hematopoietic coagulation dysfunction, or severe cardiopulmonary dysfunction;
3. Cognitive impairment or dementia caused by other factors, such as brain injury, Parkinson's disease, etc;
4. Patients who cannot cooperate with the examination (such as traditional Chinese medicine four diagnostic instruments, meridian detectors, and neuroelectrophysiological assessments).

研究实施时间:

Study execute time:

From 2021-11-01 00:00:00 To 2024-11-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-09-10 00:00:00 To 2024-05-30 00:00:00

干预措施:

Interventions:

组别:

中药安慰剂组+tDCS治疗+认知康复

样本量:

30

Group:

Chinese medicine placebo and transcranial direct current stimulation treatment stimulation and cognitive rehabilitation

Sample size:

干预措施:

中药安慰剂和tDCS刺激

干预措施代码:

Intervention:

Chinese medicine placebo and tDCS stimulation

Intervention code:

组别:

健脑益智方+ tDCS治疗+认知康复

样本量:

30

Group:

Jiannao Yizhi Formula+transcranial direct current stimulation treatment stimulation+cognitive rehabilitation

Sample size:

干预措施:

中药和tDCS刺激

干预措施代码:

Intervention:

Chinese medicine and tDCS stimulation

Intervention code:

组别:

健脑益智方+ tDCS假刺激+认知康复

样本量:

30

Group:

Jiannao Yizhi Formula+transcranial direct current stimulation treatmenttranscranial direct current stimulation treatment sham stimulation+cognitive rehabilitation

Sample size:

干预措施:

中药和tDCS假刺激

干预措施代码:

Intervention:

Chinese medicine and tDCS sham stimulation

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院望京医院 

单位级别:

三甲 

Institution
hospital:

Wangjing Hospital, China Academy of Chinese Medical Sciences

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

血管性痴呆中医辨证量表

指标类型:

主要指标

Outcome:

The scale for the differentiation of syndromes of vascular dementia

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

日常生活能力量表

指标类型:

主要指标

Outcome:

Activity of Daily Living Scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝功能

指标类型:

主要指标

Outcome:

liver function examination

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规

指标类型:

主要指标

Outcome:

blood routine examination

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

简易精神状态量表

指标类型:

主要指标

Outcome:

Mini-mental state examination

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肾功能

指标类型:

主要指标

Outcome:

kidney function examination

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血管性痴呆认知评估量表

指标类型:

主要指标

Outcome:

Vascular dementia assessment scale-cog

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 35 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用随机数字表法进行中央随机化分组,按产生的随机数字装进密不透光的信封里,将满足条件的受试者按 1:1:1的比例随机分配到试验组A、对照组B和对照组C中。

Randomization Procedure (please state who generates the random number sequence and by what method):

The random number table method was used for central randomization grouping, and the generated random numbers were put into an airtight envelope. The subjects who met the conditions were randomly assigned to test group A, control group B and control group C at a ratio of 1:1:1.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

受试者、研究者操作者均不知道试验分组情况。

Blinding:

Neither the subjects nor the researchers nor the operators were aware of the experimental grouping.

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

NO

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

NO

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2022-09-18 22:15:42